New research being presented at this year's ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27–30 April) has found compelling evidence that tuberculosis (TB) can have a lasting impact on the lungs of individuals who have been successfully treated for the disease.

The WHO BPaLM Accelerator Platform was established in January 2023, right after the update of the World Health Organization (WHO) guidelines on the treatment of drug-resistant TB in 2022. The purpose of the WHO BPaLM Accelerator Platform is to support countries and stakeholders in information exchange and technical discussions to address challenges in the adoption and implementation of the BPaLM/BPaL regimen (consisting of bedaquiline, pretomanid, linezolid and moxifloxacin, with the provision of dropping moxifloxacin in case of confirmed resistance to fluoroquinolones). This is also to support the Call to Action on rolling out of the BPaLM regimen and other short regimens for treatment of drug-resistant TB that was initiated by WHO and its multiple partners. 

The World Health Organization (WHO) Global Tuberculosis Programme is launching a call for expressions of interest, seeking collaborators to design and conduct a series of youth engagement campaigns in selected countries on ending TB.

A webinar, organized by the Global Vaccine and Immunization Research Forum (GVIRF), brought together experts to discuss the status of TB vaccine development across the value chain, from articulation of the public health and economic need for new TB vaccines through the status and strategies for product development, to the considerations for approval, policy recommendation and use.

In a recent study published in JAMA Network Open, researchers compared the performance of tuberculin skin test (TST) and interferon-γ release assays (IGRAs) in predicting tuberculosis (TB).

9 April 2024 — In a Rapid Communication issued today, the World Health Organization (WHO) is announcing updates on co-administration of treatment for drug-resistant tuberculosis and hepatitis C (HCV). The evidence suggests that concomitant treatment for HCV and multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) is feasible, with potential benefits outweighing the harms. Co-administration may increase MDR/RR-TB treatment success and reduce failures, losses to follow-up, and deaths. Adherence support for HCV treatment during MDR/RR-TB treatment is also acknowledged.

A new study by researchers with the Centers for Disease Control and Prevention and Harvard T.H. Chan School of Public Health has found significant and persistent racial disparities in tuberculosis (TB) incidence among US-born residents. The findings were published yesterday in the Annals of Internal Medicine.

The flat-dose vs weight-banded-dose cohorts did not differ with respect to TB-related unfavorable outcomes at 9, 12, and 18 months after treatment initiation.

The 1/4/6x24 Campaign and the Stop TB Partnership co-hosted a webinar on 27 March 2024 to launch the Campaign’s new report: Getting Better Faster: Delivering on the Promise of New TB Treatments. The report highlights progress and gaps in scaling up access to shorter, safer TB regimens — one month or once weekly for TB prevention, four months for drug-susceptible TB, and six months for drug-resistant TB — by the end of 2024.